Hans Thalsgaard Schambye

Title: Innovations of Hans Thalsgaard Schambye

Introduction

Hans Thalsgaard Schambye is a notable inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptide conjugates. With a total of five patents to his name, Schambye's work has had a considerable impact on medical science.

Latest Patents

Among his latest patents are innovative G-CSF conjugates. These polypeptide conjugates exhibit G-CSF activity and comprise a polypeptide with at least one introduced lysine residue and one removed lysine residue compared to the sequence of human G-CSF. They are conjugated to 2-6 polyethylene glycol moieties. The unique properties of these conjugates include low in vitro bioactivity, a long in vivo half-life, and reduced receptor-mediated clearance. This results in a more rapid stimulation of the production of white blood cells and neutrophils compared to non-conjugated recombinant human G-CSF.

Career Highlights

Schambye has worked with prominent companies in the biotechnology sector, including Maxygen Holdings Ltd. and Maxygen, Inc. His career has been marked by a commitment to advancing medical treatments through innovative research and development.

Collaborations

Throughout his career, Schambye has collaborated with talented individuals such as Torben Lauesgaard Nissen and Kim Vilbour Andersen. These partnerships have contributed to the success of his projects and the advancement of biotechnology.

Conclusion

Hans Thalsgaard Schambye's contributions to the field of biotechnology through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of medical treatments and improve patient outcomes.